Journal: MedComm
Article Title: KSQ‐4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1‐Mediated Multidrug Resistant Cancers
doi: 10.1002/mco2.70517
Figure Lengend Snippet: Influence of KSQ‐4279 on AKT and ERK transduction and analysis of KSQ‐4279 binding with ABCB1/ABCG2/ABCC1. ( A ) Western blot showed the action of KSQ‐4279 on AKT and ERK transduction. GAPDH was as an input control. ( B ) Bar graphs for the relative protein expression of the various signaling molecules detected in (A). Data were reported as mean ± SD (* p < 0.05; ** p < 0.01; *** p < 0.001). ( C ) Binding of KSQ‐4279 with ABCB1, ABCG2, and ABCC1 were assessed by CETSAs. Aliquots of cell lysates incubated with DMSO or KSQ‐4279 (10 µM) were heated at indicated temperatures, and the presence of KSQ‐4279‐bound ABCB1/ABCG2/ABCC1 proteins was analyzed via western blots. ( D ) Molecular docking of (a and b) KSQ‐4279, (c) paclitaxel, and (d) vincristine with to substrate‐binding region of ABCB1. ( E ) Molecular docking of (a and b) KSQ‐4279, (c) mitoxantrone, and (d) topotecan to the substrate‐binding area of ABCG2. ( F ) Molecular docking of (a and b) KSQ‐4279, and (c) doxorubicin to the substrate‐binding domain of ABCC1. Molecular 3D structures were obtained from the web of PubChem ( https://pubchem.ncbi.nlm.nih.gov/ ), and the crystal structures of ABC transporters were obtained from the web of Protein Data Bank ( https://www.rcsb.org/ ). The docking was performed by using software of AutoDock Vina.
Article Snippet: Doxorubicin (HY‐15142A), paclitaxel (HY‐B0015), vincristine (HY‐N0488), topotecan (HY‐13768), and verapamil (HY‐14275) were from supplier of MedChem Express (Monmouth Junction, NJ, USA).
Techniques: Transduction, Binding Assay, Western Blot, Control, Expressing, Incubation, Software